NICE rejects Pfizer’s Xalkori for ROS1-positive patients

Jan 19, 2018

The National Institute for Health and Care Excellence (NICE) turned down Pfizer’s Xalkori to treat ROS1-positive advanced non-small cell lung cancer (NSCLC).

The Agency said they will not be recommending Xalkori (Crizotinib) for previously treated ROS1-positive NSCLC, because the cost-effectiveness estimates are higher than what NICE normally considers acceptable for end-of-life treatments.

Additionally, the Agency will not recommend the drug for untreated ROS1-positive advanced NSCLC because it is too difficult to determine cost-effectiveness from the limited trials and proxy populations Pfizer used.

All is not lost for Pfizer however, as NICE believes Xalkori may have potential in ROS1-positive lung cancer, and has asked the drugmaker to consider submitting a proposal for including Xalkori in England’s Cancer Drugs Fund (CDF).

Read the NICE document


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments